IXICO PLC — AGM Information 2015

Dec 7, 2015

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 1828I

IXICO plc

07 December 2015

7 December 2015

IXICO PLC

("IXICO" or the "Company")

Result of General Meeting  

7 December 2015: IXICO plc (AIM: IXI), the brain health company, today announces that at the General Meeting held earlier today, all the resolutions proposed were unanimously passed by the requisite majorities with Resolution 2 conducted on a poll.

The full text of the resolutions can be found in the Notice of the General Meeting set out in the Circular published by the Company on 18 November 2015 and on the Company's website www.ixico.com.

Application has been made to AIM, a market of the London Stock Exchange plc, for the admission of 11,229,922 New Ordinary Shares comprising 8,852,459 Placing Shares, 2,357,463 Completion Consideration Shares and 20,000 Broker Option Shares which have been subscribed for under the terms of the Placing Agreement. It is expected that Admission will become effective at 8.00 a.m. on 8 December 2015.  Following Admission, the Company will have 26,445,586 Ordinary Shares in issue.

Unless otherwise defined, terms in this announcement shall have the same meanings as those defined in the shareholder circular dated 18 November 2015.

For further information, please contact:

IXICO plc	Tel: +44 (0) 20 3763 7499
Derek Hill, CEO
Susan Lowther, CFO
Charles Spicer, VP Corporate Development
Peel Hunt LLP (Nominated Adviser and Broker)	Tel: +44 (0) 20 7418 8900
James Steel
Oliver Jackson
Sohail Akbar
FTI Consulting Limited (Investor Relations)	Tel: +44 (0) 20 3727 1000
Simon Conway
Mo Noonan
Matthew Moss

Notes to Editors

About IXICO

IXICO, the brain health company, uses its innovative and proprietary digital platform technologies to help those involved in researching and treating serious diseases to make rapid, informed decisions targeted at improving patient outcomes.  IXICO has significant experience working with global pharmaceutical and biotechnology companies supporting clinical studies in the field of neuro-degenerative disorders including dementia, Alzheimer's disease, Huntington's disease and Multiple Sclerosis. 

More information is available on www.ixico.com 

This information is provided by RNS

The company news service from the London Stock Exchange

END

ROMLIFEAFLLDIIE